Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2580 - Autologous stem cell transplantation (ASCT) is safe and effective for the treatment of Non-Hodgkin Lymphoma (NHL) in an elderly population of patients over 65 years old: a single center experience


09 Sep 2017


Poster display session


Magalie TARDY


Annals of Oncology (2017) 28 (suppl_5): v355-v371. 10.1093/annonc/mdx373


M.P. TARDY1, J. Viotti2, A. Boscagli Melaine1, A. Thyss3, F. Peyrade4, L. Gastaud1

Author affiliations

  • 1 Medical Oncology, Centre Anticancer Antoine Lacassagne, 6100 - Nice/FR
  • 2 Biostatistics, Centre Anticancer Antoine Lacassagne, 6100 - Nice/FR
  • 3 Medical Oncology, Centre Antoine Lacassagne, 6100 - Nice/FR
  • 4 Onco-hematology, Centre Antoine Lacassagne, 06100 - Nice/FR


Abstract 2580


High-dose chemotherapy followed by ASCT is a widely used treatment for agressive or recurrent NHL for young patients (pts). Limited data are available on the feasibility and the results of this strategy for older pts, who are often excluded from agressive treatment. This study aimed at comparing pts ≥65 years old(yo) to a younger pts’ population in term of tolerance, safety and results of ASCT.


We did a retrospective study in one center in France. We included every consecutive pts treated by ASCT for NHL from May 2007 to January 2016. We collected data on the characteristics of the pts and their disease, previous treatments, and tolerance and outcome after ASCT.


48 pts ≥ 65 yo (mean: 49.5) and 129 < 65 yo (mean: 68.7) at the time of the transplant were included. The most common histology was diffuse large B cell lymphoma (p = 0.205). There were only 2 differences between the 2 groups. First, the number of pts with comorbidities was higher in the elderly population (p = 0.016), especially cardio-vascular (p 


High-dose chemotherapy followed by ASCT is as safe and effective in a population of pts ≥65 yo compared to a younger population. Agressive treatment could be considered earlier in the management of elderly pts and should not be excluded only depending on the age of the patient.

Clinical trial identification

Legal entity responsible for the study

Centre antoine Lacassagne




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.